Scientists Are Trying to Rebuild Humanity From Raw Genetic Code
Here's what you'll learn when you read this story:
For decades, scientists have been building synthetic versions of viruses, bacteria, and yeast, but now U.K. scientists are setting their sights on the human genome.
Building a synthetic genome would be much different than gene editing, which contains smaller edits to one's own genome.
While a synthetic human genome could dramatically improve our ability to manage our health, it could also be a deadly weapon if used for nefarious purposes.
The ethical duality of scientific discovery is nothing new. The most dramatic example is, of course, splitting the atom, which delivered a promising new energy source as well as weapons of mass destruction. A more recent example—the internet—was an unprecedented way to access the sum total of human knowledge, and it also became an insidious vector of mass misinformation. Now scientists are embarking on a new scientific journey, one that could bring unimaginable benefits for human health while also providing the tools for immense destruction.
We're going to synthesize the human genome.
Over the next five years, the Synthetic Human Genome Project (SynHG), funded by the world's largest medical charity Wellcome Trust (which was also a partner of the Human Genome Project completed in 2003), will work with scientists from Cambridge, Kent, Manchester, Oxford, and Imperial College London to build the foundational tools necessary to rebuild the human genome from scratch. This is different than gene editing, which typically involves much smaller changes to an organism's original DNA.
'With recent technological advances, the SynHG project is at the forefront of one of the most exciting areas of scientific research,' Wellcome's Michael Dunn said in a press statement. 'Through creating the necessary tools and methods to synthesize a human genome, we will answer questions about our health and disease that we cannot even anticipate yet, in turn transforming our understanding of life and wellbeing.'
In an interview with the BBC, Julian Sale, a member of the Molecular Biology in Cambridge who is part of the study, said that a synthetic human genome could improve the lives of humans as they age. This focus on healthspan—improving the quality of life for the years we do have—over lifespan is something medical professionals have been urging for years, and a synthetic human genome could address a wide variety of maladies that impact our quality of life in old age.
And then, there's the other side of the scientific coin.
While a synthetic genome could help generate disease-resistant cells or repair damaged organs or the immune system in general, the technology could also be used as a highly efficient biological weapon if it fell into the wrong hands. That's why SynHG will also develop social science programs that will examine the technology's ethical, legal, and social implications.
'The genie is out of the bottle,' Edinburgh University genetic scientist Bill Earnshaw told BBC News. 'We could have a set of restrictions now, but if an organization who has access to appropriate machinery decided to start synthesising anything, I don't think we could stop them.'
When it comes to synthetic biology, the genie has actually been out of that proverbial bottle for a while now. In 2002, scientists in the U.S. first synthesized a viral genome, and since then, scientists have increased genomic complexity by synthesizing a bacterium in 2008 and a yeast organism in 2017. Of course, the human genome is leagues beyond these simple synthetic reconstructions, which is why the project scientists estimate that it could take decades to complete.
Hopefully that provides enough time for humanity to fully grapple with the implications of such a breakthrough and ensure that we don't accidentally create yet another weapon of mass destruction.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
WorldWide HealthStaff Solutions and Books For Africa deliver 40,000 medical books to Kenya
CHARLOTTE, N.C., July 3, 2025 /PRNewswire/ -- WorldWide HealthStaff Solutions (WWHS), a Medical Solutions company and leader in international direct hire recruitment, has partnered with Books For Africa, the largest shipper of donated books to the African continent, to help expand access to nursing education in underserved regions of Kenya. WWHS supported the shipment of 40,000 nursing textbooks to the Kenya Medical Training College (KMTC). These donations aim to strengthen healthcare education and empower future nurses in Kenya. 'It is exciting to see these donations going to such dedicated students and educators,' said Patrick Plonski, Executive Director of Books For Africa. 'This kind of collaboration is what drives lasting impact. It is our hope that they will advance medical care and medical training in Kenya for many years to come.' This donation comes at a time when many countries are experiencing a critical shortage of nurses, making investments in education and training more important than ever. 'These textbooks represent more than just academic resources; they symbolize opportunity, equity, and a renewed belief in the potential of every health student to transform lives across Kenya,' said Irene Karari, Director at the State Department of Diaspora Affairs in Kenya. Since 2022, WWHS has partnered with Books For Africa to donate more than 100,000 nursing textbooks to parts of Africa. It's a partnership that's deeply personal to WWHS President Louis Brownstone. 'I volunteered in Tanzania in 2008, and it opened my eyes to the power of community and education,' said Brownstone. 'Partnering with Books For Africa allows me to continue that work. With the right resources, I believe we can transform lives and communities.' Books For Africa has shipped over 63 million books to all 55 African countries since 1988. Its mission to end the book famine in Africa aligns with WWHS's mission to improve lives worldwide by connecting global professionals with healthcare employers for the best career opportunities. WORLDWIDE HEALTHSTAFF SOLUTIONS WorldWide HealthStaff Solutions specializes in direct hire international nurse recruitment, connecting healthcare employers with qualified RNs and healthcare professionals worldwide. From recruitment to relocation, we guide both parties through seamless processes to foster long-term, mutually beneficial relationships. With offices in the United States, United Arab Emirates, and the Philippines, we are positioned to serve global healthcare markets effectively. View original content to download multimedia: SOURCE Medical Solutions LLC
Medscape
an hour ago
- Medscape
Endocrine Insights: Thyroid Management Tips for PCPs
This transcript has been edited for clarity. Matthew F. Watto, MD: Welcome back to The Curbsiders . I'm Dr Matthew Frank Watto, here with my great friend and America's primary care physician, Dr Paul Nelson Williams. Paul, are thyroid nodules common? I heard they're not. Is that wrong? Paul N. Williams, MD: They're very common, Matt, and they actually become more common as we age. The reassuring thing is that most of them are benign and most of them are actually found incidentally. On the episode, we discussed how thyroid nodules are becoming even more common now that low-dose lung cancer screening is more prevalent. It's wonderful that the screening is more commonplace, but we're finding many incidental things, including thyroid nodules, on these scans. One nice thing to tell patients when we're starting the initial workup is that, by and large, these are extraordinarily common and they are usually benign — though not always, and we'll get to that in a little bit. Matt, if someone were to have a thyroid nodule, what kind of symptoms would you be asking the patient about? Watto: I would not have thought of this, but one of our guests, Dr Chindris, said that she asked people about neck tightness. That can be one of the symptoms that patients will have. She also asks about compressive symptoms, voice changes, and the classic hyperthyroid or hypothyroid symptoms (eg, heat intolerance, palpitations). Dr Chindris also mentioned that she had one patient who experienced a personality change and the family thought it might be related to the thyroid. This personality change did end up getting better once the patient had their hyperthyroidism treated. This might have been anecdotal, but I thought it was a cool anecdote. Take that for what you will, audience, but I guess personality changes could be on the list of symptoms as well. Williams: I guess it's one of the things that we always check when someone is feeling different or behaving sort of "off." So, maybe this validates that to some extent. Watto: But Paul, I'm going to be real with America here: I don't know that I've ever felt someone's thyroid and been able to absolutely, confidently state that they have a dominant nodule on a certain side of the neck. I'm good at noticing if someone's thyroid is so big that I can visibly notice it without even touching them, but thyroid nodules are difficult to feel. Tell us a little bit about that, Paul. You're the physical exam guy. Williams: If I remember the episode correctly, it turns out we miss about half of thyroid nodules on physical examination, even when they are over a centimeter. They're just tough and they're really hard to feel, especially if they're less than 1 centimeter. If they're located posteriorly, your chances are really sort of slim to none. These are not typically things that we find on examination. If they're large enough, I suppose that you could feel them, but don't beat yourself up. We also discussed the various techniques used for physical exams. When we were in medical school, the technique was to "stalk" the patient from behind and wrap your hands gently around their neck. You can also have the patient drink out of a straw. Watto: I think on the episode you asked, "So, how are we doing this? Are we still sneaking up behind them and choking them?" I like the approach that Dr Susan Mandel uses. She said she examines from the front, one side at a time, using her thumb. I think that's a good way to go. Williams: The one side at a time is clutch, for sure. Watto: And it's okay to give a patient a cup of water to have them swallow so you can feel the thyroid go up and down. I had stopped doing that for a little while — probably because of laziness; there aren't many cups in my office — but I think it's a good practice. Williams: Especially if you're feeling thyroids all day. Watto: Paul, the testing for this is pretty simple. Thyroid-stimulating hormone (TSH) is still going to be the workhorse here. Then, if you find a nodule, you're determining if it's a hot nodule or if the person could have Graves disease, depending on what you're seeing or feeling on exam. You don't necessarily have to get free T4 or T3 for every single person, but sometimes you can. We also asked about calcitonin because that had come up. There's not really a role for calcitonin anymore because if you are proceeding with fine-needle aspiration (FNA), they have these molecular tests that allow you to figure out which type of thyroid cancer it might be. So, it's just a pretty basic work workup. The TSH and then ultrasound can really shine here. Paul, have you ever ordered a radionuclide thyroid scan? Williams: No, I have not. I think I've seen it on certain algorithms and thought, Boy, if I'm thinking about ordering one of those, I should probably have the patient see endocrinology anyway, as is my way. I've never pulled the trigger on one myself, and I'm not even sure I've seen one ordered by endocrinology — at least not in the past 5 years, I don't think. Watto: Dr Chindris said she might order them sometimes, like in circumstances where you may be pre-oping a patient. But nowadays, even if someone is seeing an endocrinologist, they're not necessarily getting them. In primary care, if you're practicing on your own, you're probably not going to be ordering these too often. I don't think it's necessarily the wrong thing to do; you just don't have to do it. Williams: There are often easier ways to go about it, I think. Watto: And when you get the ultrasound report, it will have a TI-RADS — much like they have a BI-RADS for mammograms — and the higher the number, the worse it is. It goes from 1 to 5, with 5 being highly suspicious. If you do a FNA, you'll receive Bethesda categories which go from 1 to 6, with 6 being malignant and 1 being nondiagnostic. It's too much to get into on this video, but if you want to hear more, definitely check out the full episode where we talk through those. Paul, let's talk about GLP-1 agonists. Tell me if this is wrong, but I believe that everyone who's on a GLP-1 agonist should have yearly or twice-yearly thyroid ultrasounds, just as standard practice. Williams: That might be a bit overaggressive. Most people watching this probably know that if a patient has either a personal or family history of multiple endocrine neoplasia (MEN), that would be a contraindication for GLP-1 agonists. I think many of us have gotten a little bit squirrely in terms of thyroid cancer, in general. If there's a history of papillary thyroid cancer, we wonder, Ooh, is this still okay? When these agents were starting to be used, we probably looked it up every time and still had a little bit of trepidation about initiating GLP-1 agonist therapy. But our guests say they have plenty of patients with history of thyroid cancer — no, not medullary, but other differentiated types — who receive GLP-1 agonists, and our guests did not have any underlying concerns about this treatment. So, I don't know if we need to be doing serial ultrasounds. But Matt, I oftentimes feel like patients come to us and they may not know what specific type of thyroid cancer they have. Do you remember the party trick we can use to differentiate that? Watto: So, what you're saying, Paul, is that I don't have to routinely order a thyroid ultrasound if someone's on a GLP with agonist, but I should ask them if they have medullary thyroid cancer in their family or if they've had MEN2A. Then, if they're not sure what type of cancer they've had, you can ask them, "Have you been treated with radiation or thyroid suppression?" If they have been treated with either of those options, it's a good signal that they were probably treated for a well-differentiated thyroid cancer. You would not treat medullary thyroid cancer with radiation or suppressive doses of levothyroxine. That's a good way to figure out what type of thyroid cancer they have. In terms of anaplastic thyroid cancer, unfortunately it has such a poor prognosis that you're probably not going to be meeting someone 10 years down the line who doesn't remember which type they had. Those patients know if they had anaplastic thyroid cancer. So, the research and the party line right now would suggest it is safe to give GLP-1 agonists to patients who have had thyroid cancer or who have thyroid nodules. The only circumstance where GLP-1 agonists are not recommended is if they have medullary thyroid cancer or MEN2A. That's good news, Paul, because a lot of doctors out there are prescribing these for patients, and thyroid cancer is relatively common.
CNN
an hour ago
- CNN
Supreme Court agrees to review bans on transgender athletes joining teams that align with their gender identity
The Supreme Court on Thursday agreed to decide whether states may ban transgender students from playing on sports teams that align with their gender identity, revisiting the issue of LGBTQ rights in a blockbuster case just days after upholding a ban on some health care for trans youth. The decision puts the issue of transgender rights on the Supreme Court's docket for the second year in a row and is by far the most significant matter the justices have agreed to hear in the term that will begin in October. In a significant loss for transgender advocates, a 6-3 majority of the Supreme Court ruled on June 18 that Tennessee could bar trans youth from accessing puberty blockers and hormone therapy. Though the state's law also bars surgeries, they were not at issue in the high court's case. The court is likely to decide the case by early next summer.
